The mutational landscape of colorectal cancer (CRC) does not enable predictions to be
made about the survival of patients or their response to therapy. Instead, studying the …

Organoids—cellular aggregates derived from stem or progenitor cells that recapitulate organ
function in miniature—are of growing interest in developmental biology and medicine …

In tissue engineering and regenerative medicine, a biomaterial provides mechanical support
and biochemical signals to encourage cell attachment and modulate cell behaviour …

Current practices in drug development have led to therapeutic compounds being approved
for widespread use in humans, only to be later withdrawn due to unanticipated toxicity …

The current drug development pipeline takes approximately fifteen years and $2.6 billion to
get a new drug to market. Typically, drugs are tested on two-dimensional (2D) cell cultures …

Despite many advances and optimization in colon cancer treatment, tumor recurrence and
metastases make the development of new therapies necessary. Colon cancer stem cells …

Current drug development techniques are expensive and inefficient, partially due to the use
of preclinical models that do not accurately recapitulate in vivo drug efficacy and cytotoxicity …

Over 1 million burn injuries are treated annually in the United States, and current tissue
engineered skin fails to meet the need for full-thickness replacement. Bioprinting technology …

Human organotypic and organoid cultures provide increasingly life‐like models of
tissue/organ development and disease, enable more realistic drug screening, and may …

The superiority of in vitro 3D cultures over conventional 2D cell cultures is well recognized
by the scientific community for its relevance in mimicking the native tissue architecture and …